Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years–Four states, 2007
Paul A. Romitti(Faculty of Public Health), Paulo Santos‐Costa, Michael Adams, Katherine A. James(Colorado School of Public Health), Gideon Zamba(University of Iowa), Emma Ciafaloni(University of Rochester Medical Center), Lisa A. Miller(University of California, Davis), Charlotte M. Druschel(New York State Department of Health), Katherine D. Mathews(University of Iowa), Carolyn M. Constantin(Centers for Disease Control and Prevention), Deborah Fox, Soman Puzhankara, Christopher Cunniff(Cornell University), Jennifer Andrews(University of Arizona), S. Pandya(Strong Memorial Hospital), Dennis J. Matthews, Lijing Ouyang, Daniel Mandel
MMWR Morbidity and Mortality Weekly Report
September 30, 2009
Cited by 107
Related Papers
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
|The Lancet Neurology|2009|2k
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care
|The Lancet Neurology|2009|1.2k
Randomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular Dystrophy
|New England Journal of Medicine|1989|518
MELAS: Clinical features, biochemistry, and molecular genetics
|Annals of Neurology|1992|508
Hypertensive Disorders in Pregnancy and Mortality at Delivery Hospitalization — United States, 2017–2019
|MMWR Morbidity and Mortality Weekly Report|2022|442